Position in ALKS
as of Jun 30, 2026
· filed Aug 3, 2026
Position Value
$314,452
-$98,941 QoQ
Shares Held
6,001
-48.7% QoQ
Ownership
0.004%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
#277
of 423 holders
Holding Since
Mar 2024
6 quarters on record
Common Shares in ALKS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Summit Global Investments holds $8,262,843 across 6 Drug Manufacturers - Specialty & Generic names. ALKS ranks #5 (3.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
29,424 | $4,959,120 | |
| 2 | TAK |
Takeda Pharmaceutical Co Ltd
|
89,173 | $1,429,443 | |
| 3 | UTHR |
UNITED THERAPEUTICS Corp
|
1,863 | $1,009,429 | |
| 4 | PAHC |
Phibro Animal Health Corp
|
10,958 | $344,081 | |
| 5 | ALKS |
Alkermes plc.
This page
|
6,001 | $314,452 | |
| 6 | SUPN |
Supernus Pharmaceuticals, Inc.
|
4,436 | $206,318 |
All Filings in ALKS
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $314,452 | 6,001 | Shares | Sole | 2026-08-03 | |
| 2026-03-31 | $413,393 | 11,691 | Shares | Sole | 2026-05-07 | |
| 2025-12-31 | $829,942 | 29,662 | Shares | Sole | 2026-02-18 | |
| 2025-09-30 | $598,140 | 19,938 | Shares | Sole | 2025-11-03 | |
| 2024-06-30 | $1,128,072 | 46,808 | Shares | Sole | 2024-07-22 | |
| 2024-03-31 | $1,079,957 | 39,895 | Shares | Sole | 2024-04-29 | |
| No filing history on record for this holder in this stock. | ||||||